| Updated:
BlackRock calls for Pfizer talks
ASTRAZENECA’S biggest shareholder BlackRock is urging management to re-engage with Pfizer over a potential takeover once a three-month hiatus on the two sides discussing a deal is lifted.
The fund manager is understood to have asked the UK drug giant to engage with its US rival. While backing the decision to refuse a £55-per-share offer on Monday, the investor is keen on the two sides resuming talks. BlackRock’s move was first reported by Sky News.